ArticleFrontiers in oncology2020

miR-452 Reverses Abnormal Glycosylation Modification of ERα and Estrogen Resistance in TNBC (Triple-Negative Breast Cancer) Through Targeting UGT1A1.

Yan Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.